EUVIMEDEUVIMED entdecken
Open Access

Germline Cancer Predisposition Results From the National Cancer Institute—Children's Oncology Group Pediatric MATCH Trial

Sarah Scollon iD, Sharon E Plon iD, Steven Joffe iD, Jaclyn A Biegel iD, Shashikant Kulkarni, George Miles iD, David R Patton iD, Brent Coffey, Cynthia L Winter, Gregory J Tsongalis, Mark J Routbort iD, Nilsa C Ramirez iD und 15 weitere

JCO Precision Oncology · 2025-10 · (9)

DOI: 10.1200/po-25-00742 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025-10. Verfasst von Sarah Scollon und 26 weiteren Autor:innen. Beteiligte Einrichtung: Texas Children's Cancer and Hematology Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX. Hauptthemen laut MEDLINE: Germ-Line Mutation, Neoplasms, Genetic Predisposition to Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Precision oncology trials have generally focused on tumor testing to identify actionable alterations. The National Cancer Institute—Children's Oncology Group Pediatric MATCH trial incorporated return of germline results to assess feasibility of reporting in a cooperative group setting and characterize germline cancer predisposition in patients with refractory cancers. PATIENTS AND METHODS Tumor and blood DNA from patients 1-21 years of age with treatment-refractory solid tumors, non-Hodgkin lymphomas, or histiocytic disorders underwent cancer gene panel sequencing. Clinical germline reports returned to 151 study sites included pathogenic/likely pathogenic (P/LP) germline variants found in 38 cancer predisposition genes (CPGs). European Society of Medical Oncology (ESMO) recommendations for germline follow-up of tumor variants in CPGs were assessed. RESULTS Both tumor and germline reports were completed for 1,167 patients (87.5% of enrolled). A total of 295 tumor reports (25%) included 361 CPG variants of which 70 variants (19.4%) were found in the germline sample. Three additional germline-only CPG variants resulted in 73 (6.3%) of 1,167 germline reports containing variants across 21 CPGs previously associated with pediatric and/or adult cancers. Among frequently mutated CPGs in tumors, concurrent germline findings ranged from 8/32 NF1 (25.0%) and 25/163 TP53 (15.3%) to zero of 27 ALK and 18 PTEN tumor variants. ESMO guidelines recommended clinical follow-up for 110 (30.5%) of 361 tumor CPG variants which included 40 (57.1%) of 70 germline variants. CONCLUSION Coordinated germline and tumor panel testing was feasible and revealed P/LP CPG variants in 6.3% of the Pediatric MATCH cohort. Tumor variant fraction, germline association of CPG with tumor type, and adult-oriented guidelines were not predictive of germline status, emphasizing the need for systematic germline follow-up after tumor genomic testing for pediatric patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Germ-Line MutationNeoplasmsGenetic Predisposition to DiseaseHumansChildAdolescentMaleChild, PreschoolFemaleYoung AdultUnited StatesInfantNational Cancer Institute (U.S.)

Autor:innen und Institutionen

  • Texas Children's Cancer and Hematology Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
  • Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX.
  • Department of Medical Ethics & Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, CA.
  • Keck School of Medicine, University of Southern California, Los Angeles, CA.

ORCID-Profile: Sarah Scollon, Sharon E Plon, Steven Joffe, Jaclyn A Biegel, George Miles, David R Patton, Mark J Routbort, Nilsa C Ramirez, Jin Piao, Stacey L Berg, Elizabeth Fox, Brenda Weigel, Douglas S Hawkins, Margaret Mooney, Naoko Takebe, James V Tricoli, Katherine A Janeway, Nita L Seibel, D Williams Parsons

Förderung

  • NCI NIH HHS

Zitieren

APA

Scollon, S., Plon, S. E., Joffe, S., Biegel, J. A., Kulkarni, S., Miles, G., Patton, D. R., Coffey, B., Winter, C. L., Tsongalis, G. J., Routbort, M. J., Ramirez, N. C., Saguilig, L., Piao, J., Alonzo, T. A., Berg, S. L., Fox, E., Weigel, B., Hawkins, D. S., …, & NCI-COG Pediatric MATCH Germline Reporting Committee (2025). Germline Cancer Predisposition Results From the National Cancer Institute—Children's Oncology Group Pediatric MATCH Trial. JCO Precision Oncology. https://doi.org/10.1200/po-25-00742

Vancouver

Scollon S, Plon SE, Joffe S, Biegel JA, Kulkarni S, Miles G, et al. Germline Cancer Predisposition Results From the National Cancer Institute—Children's Oncology Group Pediatric MATCH Trial. JCO Precision Oncology. 2025. doi:10.1200/po-25-00742

BibTeX
@article{Scollon2025,
  author = {Scollon, Sarah and Plon, Sharon E and Joffe, Steven and Biegel, Jaclyn A and Kulkarni, Shashikant and Miles, George and Patton, David R and Coffey, Brent and Winter, Cynthia L and Tsongalis, Gregory J and Routbort, Mark J and Ramirez, Nilsa C and Saguilig, Lauren and Piao, Jin and Alonzo, Todd A and Berg, Stacey L and Fox, Elizabeth and Weigel, Brenda and Hawkins, Douglas S and Abrams, Jeffrey S and Mooney, Margaret and Takebe, Naoko and Tricoli, James V and Janeway, Katherine A and Seibel, Nita L and Parsons, D Williams and NCI-COG Pediatric MATCH Germline Reporting Committee, NCI-COG Pediatric MATCH Germline Reporting Committee},
  title = {Germline Cancer Predisposition Results From the National Cancer Institute—Children's Oncology Group Pediatric MATCH Trial},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po-25-00742}
}
Kostenlos starten →